查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1807516

核医市场按产品类型、给药方式、用途、应用和最终用户划分－2025-2030 年全球预测

Nuclear Medicine Market by Product Type, Mode Of Administration, Usage, Application, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计核医市场规模在 2024 年将达到 146 亿美元，在 2025 年将成长至 160.5 亿美元，在 2030 年将达到 270.4 亿美元，复合年增长率为 10.80%。

主要市场统计数据
基准年2024年 146亿美元
预计2025年 160.5亿美元
预计2030年 270.4亿美元
复合年增长率（%） 10.80%

探索不断发展的核子医学领域：深入了解推动全球医疗保健进步的最新诊断和治疗创新

核子医学已成为现代医疗保健的基石，利用放射性同位素的独特特性实现精准诊断和标靶治疗。从早期的伽马摄影机成像到如今先进的诊疗方法，该领域不断发展，以应对日益增长的个人化医疗需求、分子生物学的进步以及成像硬体和放射性药物化学的持续创新。价值链上的相关人员——放射性药物开发商、设备製造商、临床医生和监管机构——都在应对不断变化的临床指南、不断扩展的适应症以及日益严格的安全和供应审查所带来的挑战。

确定影响核子医学的变革性变化，从传统的同位素方案到多种模式的突破性放射性药物发展

在放射性药物研发的突破和整合技术创新的推动下，核医领域正经历一场变革性的转变。近年来，针对特定生物标记物定制的新型分子示踪剂的激增，使临床医生能够以前所未有的灵敏度检测病理过程。同时，数位影像检测器和先进的断层扫描重建演算法提高了影像解析度和量化能力。这两种趋势正朝着无缝整合正子断层扫描 (PET)、单光子发射电脑断层扫描 (SEP) 和电脑断层扫描 (CT) 的混合平台发展，从而促进对疾病的更全面观察。

评估 2025 年美国关税对核医供应链、研究合作动态与跨国放射性药物贸易流量的累积影响

2025年美国关税的实施为核医供应链带来了新的复杂性，影响了同位素材料和影像设备的进口。随着关键原材料和专用零件关税的生效，製造商面临生产成本上升和物流限制的压力。这项变更促使一些製造商重新思考筹资策略，投资国内同位素生产设施，并寻求垂直整合，以减轻进口关税的影响。

透过深入了解产品类型、管理模式、用途、应用和最终用户概况等关键市场细分，明确您的策略

市场区隔洞察揭示了一个支援策略规划和资源配置的多层面框架。依产品类型，市场分为诊断性放射性药物（正子断层扫描同位素和单光子发射电脑断层扫描同位素）和治疗性核子医学（包括近距离放射治疗同位素，例如铯-131、碘-125、铱-192和钯-103，以及使用α和β发射核素的放射性药物治疗）。这种分层分类有利于针对临床效用、製造复杂性和监管途径进行有针对性的分析。

分析美洲、欧洲、中东和非洲以及亚太市场的区域动态和优先驱动因素，以确定核医扩大策略

核子医学的区域动态反映了美洲、欧洲、中东和非洲以及亚太地区不同的投资模式、基础设施成熟度和法规环境。在美洲，北美成熟的医疗保健体係正在推动先进影像平台和尖端放射性追踪剂的广泛应用，而南美市场则专注于扩展基础 PET 和 SPECT 功能，以满足日益增长的诊断需求。该地区的相关人员正在平衡对经济高效的供应解决方案的需求和对最新诊疗通讯协定的需求。

介绍推动核医价值链创新、卓越营运和竞争优势的关键产业相关人员和策略伙伴关係

主要企业正在建立策略联盟，以加速产品线开发并扩大其市场份额。一家全球诊断影像设备製造商正与放射性药物开发商合作，共同开发端到端解决方案，以优化新型示踪剂的扫描器效能。特种同位素製造商正与受託製造厂商合作，以扩大针对性α和β发送器的生产；核医药局正透过与医院和诊断中心授权合约来扩大其地理覆盖范围。

可操作的建议，使产业领导者能够优化核医学生态系统的供应链、法规遵循和投资重点

为了因应地缘政治和贸易中断，产业领导者应优先考虑透过投资区域产能和签订联盟供应协议来实现同位素采购的多元化。透过积极参与标准机构加强监管参与，有助于协调主要市场的核准流程，并缩短新化合物的临床应用时间。此外，将先进的数据分析技术融入采购和库存管理，可提高预测准确性，并最大限度地减少短寿命同位素的浪费。

了解核子医学市场情报中用于确保资料完整性、全面的市场分析和可靠检验的严格调查方法

本报告中的见解基于严谨的调查方法，该方法结合了一级研究和二级研究、数据三角测量和专家检验。对同行评审出版物、专利申请和监管资料库的广泛审查提供了基础知识。我们也对放射性药物製造商、诊断影像设备供应商、学术研究中心和监管机构的高阶主管进行了深入访谈，以获得有关新兴趋势和产业挑战的第一手观点。

摘要关键发现和策略意义，帮助相关人员利用新兴趋势，塑造核子医学领域的未来

先进示踪剂的研发、数位成像技术的突破以及不断演变的法律规范的融合，正在将核医学重塑为一个真正精准驱动的领域。从2025年关税对供应链韧性的影响，到对不同产品类型和应用领域细分市场的洞察，本分析凸显了策略适应性和协作创新的重要性。区域动态进一步凸显了采取量身定制的方法以解决区域基础设施、监管协调和市场成熟度问题的需求。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 扩展氟-18放射性示踪剂用于肿瘤靶向PET成像
  • 整合人工智慧和机器学习，实现 PET/CT 影像分析自动化，提升诊断准确性
  • 开发将诊断影像同位素（如镓-68）与治疗同位素（如镏-177）结合的诊疗对，用于个人化癌症治疗
  • 由于全身影像灵敏度提高且辐射剂量减少，全身 PET影像检查仪的采用率不断提高
  • 迴旋加速器和放射性药物基础设施的进步，以支持本地生产短寿命放射性核种并减少供应链限制
  • 新型α发射放射性核种疗法的监管发展和核准，例如基于锕-225的前列腺癌治疗方法。
  • 云端基础的数位平台的实施，用于多中心研究中核子医学摄影数据的安全共用和协作
  • 开发经济高效的紧凑型迴旋加速器，以分散 PET 示踪剂的生产并扩大其在社区医院的覆盖范围
  • 针对 PSMA 和 HER2 的新兴放射免疫结合物，可精准应用于转移性疾病
  • 应用深度学习演算法优化放射性药物合成通讯协定并提高产量一致性

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章：2025年美国关税的累积影响

第八章 核子医学市场（依产品类型）

  • 诊断放射性药物
    • 正子断层扫描（PET）同位素
    • 单光子发射电脑断层扫描 (SPECT) 同位素
  • 治疗性核子医学
    • 近距离放射治疗近距离放射治疗
      • 铯-131
      • 碘-125
      • 铱192
      • 钯-103
    • 放射性药物治疗
      • α发射体
      • β射线发射器

9. 依管理方法分類的核子医学市场

  • 静脉注射
  • 口服

第 10 章 核子医学市场：依用途

  • 诊断程序
    • PET扫描仪
      • 模拟PET
      • 数字PET
    • SPECT 扫描仪
  • 治疗程序

第 11 章核医市场：按应用

  • 心臟病
  • 内分泌
  • 胃肠病学
  • 神经
  • 瘤
  • 整形外科
  • 呼吸系统医疗设备

第 12 章 核子医学市场（依最终使用者）

  • 学术研究机构
  • 诊断中心
  • 医院
    • 公立医院
    • 私立医院

第 13 章：美洲核子医学市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第十四章欧洲、中东和非洲的核子医学市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

第十五章：亚太核子医学市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • FPNV定位矩阵2024
  • 竞争分析
    • 3B Pharmaceuticals GmbH
    • Actinium Pharmaceuticals, Inc.
    • BJ Madan & Co.
    • Bayer AG
    • Bracco SpA
    • BWX Technologies, Inc.
    • Clarity Pharmaceuticals
    • Curium
    • Eli Lilly and Company
    • GE HealthCare
    • IBA
    • Institute of Isotopes Co., Ltd
    • Isotopia Molecular Imaging Ltd.
    • Jubilant Pharma Limited
    • Lantheus Holdings, Inc.
    • Medi-Radiopharma Co., Ltd.
    • Nordion
    • Northstar Medical Technologies LLC
    • Novartis AG
    • Nusano, Inc.
    • PeptiDream Inc.
    • Radiopharm Theranostics Limited
    • SHINE Technologies, LLC
    • Siemens Healthineers AG
    • Sinotau Pharmaceuticals Group
    • South African Nuclear Energy Corporation
    • State Atomic Energy Corporation Rosatom
    • Thor Medical AS by Nordic Nanovector ASA

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-A339DAEFAF4C

The Nuclear Medicine Market was valued at USD 14.60 billion in 2024 and is projected to grow to USD 16.05 billion in 2025, with a CAGR of 10.80%, reaching USD 27.04 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 14.60 billion
Estimated Year [2025] USD 16.05 billion
Forecast Year [2030] USD 27.04 billion
CAGR (%) 10.80%

Navigating the Evolving Nuclear Medicine Landscape: Foundational Insights Into Modern Diagnostics and Therapeutic Innovations Driving Global Healthcare Progress

Nuclear medicine has emerged as a cornerstone of modern healthcare, harnessing the unique properties of radioisotopes to enable both precise diagnostics and targeted therapies. From early gamma camera imaging to today's sophisticated theranostic approaches, the field has evolved in response to rising demand for personalized care, advances in molecular biology, and relentless innovation in imaging hardware and radiopharmaceutical chemistry. Stakeholders across the value chain-including radiopharmaceutical developers, equipment manufacturers, clinical practitioners, and regulators-are navigating a landscape shaped by shifting clinical guidelines, expanding indications, and heightened scrutiny of safety and supply security.

Against this backdrop, the convergence of digital imaging technologies, novel tracer development, and integrated data analytics is catalyzing a new era of nuclear medicine. Technological strides such as high-resolution detectors, digital positron emission tomography, and hybrid imaging platforms are amplifying diagnostic accuracy, while breakthroughs in targeted alpha and beta emitters are unlocking therapeutic options for oncology, cardiology, and neurology. This introduction lays the foundation for an in-depth exploration of the forces reshaping nuclear medicine, setting the stage for a detailed examination of market drivers, segmentation insights, regional dynamics, and strategic imperatives that will define the industry's trajectory through 2025 and beyond.

Identifying Transformational Shifts Reshaping Nuclear Medicine From Traditional Isotope Protocols to Breakthrough Radiopharmaceutical Developments Across Multiple Modalities

The nuclear medicine landscape is undergoing transformative shifts, originating from breakthroughs in radiopharmaceutical discovery and convergent technological innovations. Recent years have witnessed a surge in novel molecular tracers tailored to specific biomarkers, enabling clinicians to detect pathological processes with unprecedented sensitivity. Concurrently, digital imaging detectors and advanced tomographic reconstruction algorithms have elevated image resolution and quantification capabilities. These dual trends are converging in hybrid platforms that seamlessly integrate positron emission tomography, single photon emission computed tomography, and computed tomography, fostering a more holistic view of disease.

Beyond hardware and tracer advances, the industry is responding to evolving regulatory frameworks that emphasize safety, standardization, and harmonized licensing across jurisdictions. Governments and international bodies are working to streamline radiopharmaceutical approval pathways and improve cross-border supply arrangements, while also enforcing stringent quality controls for isotope production and handling. This regulatory momentum, combined with growing collaboration between academic research institutes and contract manufacturing organizations, is accelerating the translation of preclinical candidates into clinical-grade products. As a result, the sector is poised for a new wave of innovation, where precision diagnostics and targeted therapies coalesce to deliver more effective and efficient patient care.

Assessing the Cumulative Impact of 2025 United States Tariffs on Nuclear Medicine Supply Chains, Research Collaboration Dynamics, and Cross-Border Radiopharmaceutical Trade Flows

The introduction of United States tariffs in 2025 has injected fresh complexity into nuclear medicine supply chains, affecting both isotopic materials and imaging equipment imports. As tariffs on critical raw materials and specialized components took effect, manufacturers faced upward pressure on production costs and logistical constraints. This shift has prompted some producers to reconsider sourcing strategies, invest in domestic isotope generation facilities, and pursue vertical integration to mitigate exposure to import levies.

In tandem, collaborative research networks that once relied on seamless transnational exchange of isotopes and consumables are adjusting to new financial and regulatory burdens. Academic and clinical partners in Europe and Asia are exploring local production partnerships to ensure uninterrupted access to critical radiotracers. Meanwhile, equipment providers have intensified after-sales service and spare-parts stocking in regional hubs to circumvent tariff-driven delays. These adjustments underscore a broader rethinking of the global nuclear medicine ecosystem, where supply resilience and cost containment have become as vital as clinical efficacy for sustaining growth and innovation.

Uncovering Key Market Segmentation Insights Across Product Types, Administration Modes, Usage Categories, Clinical Applications, and End User Profiles for Strategic Clarity

Insights into market segmentation reveal a multifaceted framework that underpins strategic planning and resource allocation. Across product types, the field is delineated into diagnostic radiopharmaceuticals-encompassing positron emission tomography isotopes and single photon emission computed tomography isotopes-and therapeutic nuclear medicine, which includes brachytherapy isotopes such as cesium-131, iodine-125, iridium-192 and palladium-103, alongside radiopharmaceutical therapies employing both alpha emitters and beta emitters. This layered breakdown enables targeted analysis of clinical utility, manufacturing complexity, and regulatory pathways.

The mode of administration distinguishes between intravenous injection and oral ingestion, reflecting divergent pharmacokinetic profiles and patient convenience considerations. Usage patterns are classified into diagnostic procedures and therapeutic procedures, with diagnostic workflows segmented by PET scanner modalities-ranging from analog to digital systems-and SPECT scanners designed for high-resolution imaging. Clinical application categories span cardiology, endocrinology, gastroenterology, neurology, oncology, orthopedics and pulmonology, each driving unique demand trajectories based on disease prevalence and standard-of-care protocols. Finally, end users include academic and research institutes, specialized diagnostic centers, and hospitals-which themselves are segmented into government and private facilities-highlighting the varying operational requirements and procurement processes across the healthcare spectrum.

Analyzing Regional Dynamics and Priority Drivers in the Americas, Europe Middle East Africa, and Asia Pacific Markets for Informed Decisions in Nuclear Medicine Expansion Strategies

Regional dynamics in nuclear medicine reflect divergent investment patterns, infrastructure maturity, and regulatory environments across the Americas, Europe Middle East Africa and Asia Pacific. In the Americas, established healthcare systems in North America drive high adoption of advanced imaging platforms and cutting-edge radiotracers, while Latin American markets focus on expanding basic PET and SPECT capacity to address growing diagnostic needs. Stakeholders in this region are balancing the need for cost-effective supply solutions with demand for the latest theranostic protocols.

Europe Middle East Africa presents a mosaic of adoption rates, with Western Europe leading in standardized regulatory frameworks and collaborative research consortia. Emerging markets in the Middle East and Africa are at earlier stages of establishing isotope generation and distribution networks, often leveraging public-private partnerships to accelerate capability building. Regulatory harmonization efforts are underway to reduce complexity for multinational clinical trials and cross-border collaborations.

Asia Pacific's nuclear medicine sector is characterized by rapid capacity expansion in countries such as China, Japan and India, driven by government initiatives to enhance domestic isotope production and bolster nuclear medicine infrastructure. This region is also a hotbed for technological innovation, with local manufacturers investing heavily in digital imaging detectors and mobile cyclotron installations. As a result, Asia Pacific is emerging as both a consumer and producer of advanced radiopharmaceutical solutions.

Profiling Leading Industry Stakeholders and Strategic Partnerships Fueling Innovation, Operational Excellence, and Competitive Advantage in the Nuclear Medicine Value Chain

Leading companies are forging strategic alliances to accelerate pipeline development and reinforce market presence. Global imaging equipment manufacturers have partnered with radiopharmaceutical developers to co-develop end-to-end solutions that optimize scanner performance for novel tracers. Specialized isotope producers are collaborating with contract development and manufacturing organizations to scale up production of targeted alpha and beta emitters, while nuclear pharmacies are expanding their geographic footprint through licensing agreements with hospitals and diagnostic centers.

In parallel, a new generation of agile start-ups is leveraging proprietary radiochemistry platforms to engineer next-generation theranostic agents, often in joint ventures with academic research institutions. These collaborations are fostering a robust innovation ecosystem, where intellectual property is shared under structured agreements to de-risk development and accelerate regulatory submissions. Equally, established pharmaceutical companies are investing in nuclear medicine capabilities through acquisitions, signaling growing recognition of radiopharmaceuticals as a core component of precision medicine portfolios.

Delivering Actionable Recommendations to Empower Industry Leaders in Optimizing Supply Chains, Regulatory Compliance, and Investment Priorities Within Nuclear Medicine Ecosystems

Industry leaders should prioritize diversification of isotope sourcing by investing in regional production capacity and forming consortium-based supply agreements to hedge against geopolitical and trade disruptions. Strengthening regulatory engagement through active participation in standards-setting bodies will help align approval processes across key markets and reduce time-to-clinic for novel compounds. Moreover, integrating advanced data analytics into procurement and inventory management can enhance forecasting accuracy and minimize waste for short-lived isotopes.

Organizations must also consider forging cross-sector alliances with digital health and artificial intelligence specialists to develop companion diagnostic platforms that personalize treatment pathways. Deploying modular cyclotron technologies in strategic locations will not only improve supply resilience but also drive down logistics costs. Finally, dedicating resources to workforce training and safety protocols will ensure that facilities maintain high compliance standards, safeguard staff and patients, and support sustainable growth in an increasingly complex environment.

Detailing Rigorous Research Methodology Employed to Ensure Data Integrity, Comprehensive Market Analysis, and Robust Validation in Nuclear Medicine Market Intelligence

This report's insights are grounded in a rigorous methodology that combines primary and secondary research, data triangulation and expert validation. An extensive review of peer-reviewed publications, patent filings and regulatory databases provided the foundational knowledge base. Detailed interviews were conducted with senior executives across radiopharmaceutical manufacturers, imaging equipment providers, academic research centers and regulatory authorities to capture firsthand perspectives on emerging trends and industry challenges.

Quantitative data sets covering production volumes, technology adoption rates and demographic trends were analyzed using statistical techniques to identify underlying patterns and correlations. Segmentation analysis was applied across product types, administration modes, clinical applications and end-user categories to ensure that findings are granular and actionable. The resulting conclusions were subjected to multiple rounds of expert review to verify accuracy and relevance, ensuring that the final report delivers robust, evidence-based insights for strategic decision making.

Summarizing Critical Findings and Strategic Implications for Stakeholders to Capitalize on Emerging Trends and Navigate the Future of the Nuclear Medicine Sector

The convergence of advanced tracer development, digital imaging breakthroughs and evolving regulatory frameworks is reshaping nuclear medicine into a truly precision-driven discipline. From the impact of 2025 tariffs on supply chain resilience to the nuanced segmentation insights across product types and clinical applications, this analysis underscores the importance of strategic adaptability and collaborative innovation. Regional dynamics further highlight the need for tailored approaches that address local infrastructure, regulatory alignment and market maturity.

Looking ahead, stakeholders who proactively invest in supply diversification, regulatory harmonization and cross-sector partnerships will be best positioned to capture the next wave of opportunities in theranostics and diagnostic imaging. By leveraging the comprehensive findings outlined in this report, decision-makers can refine their go-to-market strategies, optimize resource allocation and accelerate time-to-clinic for transformative nuclear medicine solutions. This confluence of innovation, regulation and strategic foresight will define the sector's trajectory and its impact on patient care in the coming decade.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of fluorine-18 based radiotracers for targeted PET imaging in oncology
  • 5.2. Integration of artificial intelligence and machine learning for automated PET/CT image analysis and diagnostic accuracy
  • 5.3. Growth of theranostic pairs combining diagnostic imaging isotopes like gallium-68 with therapeutic isotopes like lutetium-177 for personalized cancer treatment
  • 5.4. Increasing adoption of total-body PET scanners to improve sensitivity and reduce radiation dose in whole-body imaging studies
  • 5.5. Advancements in cyclotron and radiopharmacy infrastructure to support local production of short-lived radionuclides and reduce supply chain constraints
  • 5.6. Regulatory progress and approvals for novel alpha-emitting radionuclide therapies such as actinium-225 based treatments for prostate cancer
  • 5.7. Implementation of cloud-based digital platforms for secure sharing and collaboration of nuclear imaging data across multi-center trials
  • 5.8. Development of cost-effective compact cyclotrons to decentralize production of PET tracers and expand access in community hospitals
  • 5.9. Emergence of novel radioimmunoconjugates targeting PSMA and HER2 for precision nuclear medicine applications in metastatic disease
  • 5.10. Application of deep learning algorithms to optimize radiopharmaceutical synthesis protocols and enhance yield consistency

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Nuclear Medicine Market, by Product Type

  • 8.1. Introduction
  • 8.2. Diagnostic Radiopharmaceuticals
    • 8.2.1. Positron Emission Tomography (PET) Isotopes
    • 8.2.2. Single Photon Emission Computed Tomography (SPECT) Isotopes
  • 8.3. Therapeutic Nuclear Medicine
    • 8.3.1. Brachytherapy Isotopes
      • 8.3.1.1. Cesium-131
      • 8.3.1.2. Iodine-125
      • 8.3.1.3. Iridium-192
      • 8.3.1.4. Palladium-103
    • 8.3.2. Radiopharmaceutical Therapy
      • 8.3.2.1. Alpha Emitters
      • 8.3.2.2. Beta Emitters

9. Nuclear Medicine Market, by Mode Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous Injection
  • 9.3. Oral Ingestion

10. Nuclear Medicine Market, by Usage

  • 10.1. Introduction
  • 10.2. Diagnostic Procedure
    • 10.2.1. PET Scanners
      • 10.2.1.1. Analog PET
      • 10.2.1.2. Digital PET
    • 10.2.2. SPECT Scanners
  • 10.3. Therapeutic Procedure

11. Nuclear Medicine Market, by Application

  • 11.1. Introduction
  • 11.2. Cardiology
  • 11.3. Endocrinology
  • 11.4. Gastroenterology
  • 11.5. Neurology
  • 11.6. Oncology
  • 11.7. Orthopedics
  • 11.8. Pulmonology

12. Nuclear Medicine Market, by End Users

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Diagnostic Centers
  • 12.4. Hospitals
    • 12.4.1. Government Hospitals
    • 12.4.2. Private Hospitals

13. Americas Nuclear Medicine Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Nuclear Medicine Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Nuclear Medicine Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. 3B Pharmaceuticals GmbH
    • 16.3.2. Actinium Pharmaceuticals, Inc.
    • 16.3.3. B J Madan & Co.
    • 16.3.4. Bayer AG
    • 16.3.5. Bracco S.p.A.
    • 16.3.6. BWX Technologies, Inc.
    • 16.3.7. Clarity Pharmaceuticals
    • 16.3.8. Curium
    • 16.3.9. Eli Lilly and Company
    • 16.3.10. GE HealthCare
    • 16.3.11. IBA
    • 16.3.12. Institute of Isotopes Co., Ltd
    • 16.3.13. Isotopia Molecular Imaging Ltd.
    • 16.3.14. Jubilant Pharma Limited
    • 16.3.15. Lantheus Holdings, Inc.
    • 16.3.16. Medi-Radiopharma Co., Ltd.
    • 16.3.17. Nordion
    • 16.3.18. Northstar Medical Technologies LLC
    • 16.3.19. Novartis AG
    • 16.3.20. Nusano, Inc.
    • 16.3.21. PeptiDream Inc.
    • 16.3.22. Radiopharm Theranostics Limited
    • 16.3.23. SHINE Technologies, LLC
    • 16.3.24. Siemens Healthineers AG
    • 16.3.25. Sinotau Pharmaceuticals Group
    • 16.3.26. South African Nuclear Energy Corporation
    • 16.3.27. State Atomic Energy Corporation Rosatom
    • 16.3.28. Thor Medical AS by Nordic Nanovector ASA

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. NUCLEAR MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. NUCLEAR MEDICINE MARKET: RESEARCHAI
  • FIGURE 26. NUCLEAR MEDICINE MARKET: RESEARCHSTATISTICS
  • FIGURE 27. NUCLEAR MEDICINE MARKET: RESEARCHCONTACTS
  • FIGURE 28. NUCLEAR MEDICINE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. NUCLEAR MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 163. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 164. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 183. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 185. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 187. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 188. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 203. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 204. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 205. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 207. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 209. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 211. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 224. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 225. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 226. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 227. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 228. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 229. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 231. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 233. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 234. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 235. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 236. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 295. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 299. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 301. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 303. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 304. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 305. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 307. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 308. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 309. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 310. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 311. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 312. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 313. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 315. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 316. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 317. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 318. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 319. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 321. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 322. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 323. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 324. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 325. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 326. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 327. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 328. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 329. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 330. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 331. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY US